Samir H Barghout
Overview
Explore the profile of Samir H Barghout including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
413
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chan S, Zeng J, Young J, Barghout S, Al-Agha F, Raptis S, et al.
Clin Lung Cancer
. 2024 Nov;
26(1):e22-e32.e2.
PMID: 39578168
Background: Patients with nonsmall cell lung cancer with anaplastic lymphoma kinase (ALK) rearrangements derive a significant and durable clinical benefit from tyrosine kinase inhibitors (TKIs). However, early progression/death on treatment...
2.
Barghout S, Meti N, Chotai S, Kim C, Patel D, Brown M, et al.
Br J Cancer
. 2024 Nov;
132(2):139-153.
PMID: 39572762
The field of precision oncology has witnessed several advances that stimulated the development of new clinical trial designs and the emergence of real-world data (RWD) as an important resource for...
3.
Barghout S, Zhan L, Raptis S, Al-Agha F, Esfahanian N, Popovacki A, et al.
Lung Cancer
. 2024 Jul;
194:107898.
PMID: 39074423
Objectives: KRAS mutations, particularly KRAS, are prevalent in non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICIs) have been a frontline treatment, but recently developed KRAS-selective inhibitors, such as sotorasib,...
4.
Esfahanian N, Chan S, Zhan L, Brown M, Khan K, Lee J, et al.
Cancer Treat Res Commun
. 2023 Nov;
37:100774.
PMID: 37979334
Close monitoring after diagnosis of patients with stage I-III non-small cell lung cancer (NSCLC) may result in fitter patients with lower disease burden at the time of metastatic recurrence or...
5.
Ramachandran S, Szewczyk M, Barghout S, Ciulli A, Barsyte-Lovejoy D, Vu V
Methods Mol Biol
. 2023 Aug;
2706:149-165.
PMID: 37558947
Cellular thermal shift assay (CETSA) is based on the thermal stabilization of the protein target by a compound binding. Thus, CETSA can be used to measure a compound's cellular target...
6.
Fazzari F, Chow S, Cheung M, Barghout S, Schimmer A, Chang Q, et al.
ACS Pharmacol Transl Sci
. 2022 Nov;
5(11):1070-1078.
PMID: 36407947
Pancreatic ductal adenocarcinoma is characterized by increased generation of reactive oxygen species that can cause lethal oxidative stress. Here, we evaluated the combined inhibition of the glutathione and thioredoxin antioxidant...
7.
Barghout S, Mann M, Aman A, Yu Y, Alteen M, Schimmer A, et al.
ACS Chem Biol
. 2022 Sep;
17(10):2801-2816.
PMID: 36084291
Anticancer drug response is determined by genetic and epigenetic mechanisms. To identify the epigenetic regulators of anticancer drug response, we conducted a chemical epigenetic screen using chemical probes that target...
8.
Barghout S, Machado R, Barsyte-Lovejoy D
Biochim Biophys Acta Gene Regul Mech
. 2022 Jun;
1865(6):194840.
PMID: 35753676
Histone lysine methylation is a post-translational modification that plays a key role in the epigenetic regulation of a broad spectrum of biological processes. Moreover, the dysregulation of histone lysine methyltransferases...
9.
Barghout S
Anticancer Agents Med Chem
. 2022 Apr;
22(15):2656-2661.
PMID: 35418290
Proteolysis targeting chimeras (PROTACs) are an emerging class of targeted protein degraders that coopt the intracellular degradation machinery to selectively deplete their respective targets. PROTACs act as bifunctional degraders that...
10.
Szewczyk M, Luciani G, Vu V, Murison A, Dilworth D, Barghout S, et al.
Redox Biol
. 2022 Mar;
51:102282.
PMID: 35305370
Protein methyltransferase 5 (PRMT5) symmetrically dimethylates arginine residues leading to regulation of transcription and splicing programs. Although PRMT5 has emerged as an attractive oncology target, the molecular determinants of PRMT5...